GHRP-6 vs CJC-1295
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 6, SKF-110679
One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | GHRP-6 | CJC-1295 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHRP-6 binds to ghrelin receptors (GHSR-1a) in the hypothalamus and pituitary, triggering a strong GH release. It also activates the hunger-signaling pathway, leading to significant appetite increase. Stimulates cortisol and prolactin more than newer GHRPs. | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) |
| Administration | Subcutaneous injection, ideally fasted | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Well-studied peptide showing reliable GH release. Research demonstrates cardioprotective effects in animal models, improved wound healing, and significant appetite stimulation. Studies show 3-6 fold increase in GH levels. | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. |
Frequently Asked Questions: GHRP-6 vs CJC-1295
What is the difference between GHRP-6 and CJC-1295?
GHRP-6 is a growth hormone peptide that one of the first synthetic gh secretagogues developed. strongly stimulates gh release and significantly increases appetite through ghrelin receptor activation. CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-6 or CJC-1295?
Neither is universally "better" - the choice depends on your specific goals. GHRP-6 is typically used for growth hormone purposes, while CJC-1295 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-6 and CJC-1295 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-6 and CJC-1295 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of GHRP-6 and CJC-1295 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.